Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
HERNANDEZ-MORALES, María del Rocío y MANCILLA-HERNANDEZ, Eleazar. The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients. Rev. alerg. Méx. [online]. 2020, vol.67, n.3, pp.237-244. Epub 02-Jun-2021. ISSN 2448-9190. https://doi.org/10.29262/ram.v67i3.745.
Background:
Trimethoprim with sulfamethoxazole (TMP-SMX) is the drug of choice for the prophylaxis of AIDS-associated comorbidities.
Objective:
To compare the efficacy and safety of two schemes of desensitization to TMP-SMX in HIV-positive patients.
Methods:
A study was conducted from March 2018 to October 2019; it included HIV-positive patients who presented an adverse skin reaction to TMP-SMX; fifteen of them received desensitization scheme 1, which lasted ten days, and five patients received scheme 2, which lasted six hours.
Results:
The average age of the patients who received scheme 1 was of 27.4 ± 5.7 years, while the average age of patients who received scheme 2 was of 33.6 ± 8 years. At baseline, the demographic, clinical, and immunological variables did not show significant differences between both groups (p> 0.05). In both groups, an efficacy of 100% was obtained and, in terms of safety, only three patients in group 1 presented rash and pruritus, however, the procedure was not suspended; the previous tolerated dose was resumed and, subsequently, the desensitization procedure continued.
Conclusions:
Both schemes of desensitization to TMP-SMX showed efficacy and safety in HIV-positive patients, who frequently present adverse reactions to these medications.
Palabras llave : Adverse drug reaction; Trimethoprim-sulfamethoxazole; Desensitization; Infection by human immunodeficiency virus.